China Medical System Gains NMPA Nod for Uterine Fibroid Drug Trial

SGX Filings2025-09-26

China Medical System Holdings Limited said the National Medical Products Administration approved a clinical trial application for its oral GnRH receptor antagonist CMS-D002 aimed at treating uterine fibroids on Sep, 25 2025, with the formal approval documents received on Sep, 26 2025.

The trial will evaluate the safety and efficacy of CMS-D002, a small-molecule therapy designed to suppress estrogen and progesterone by competitively blocking GnRH receptors. The candidate had already entered Phase I testing for endometriosis after a prior NMPA clearance on Feb, 06 2024.

The company stated it is preparing to start the newly approved study and noted that future development of CMS-D002 could include indications such as prostate cancer. No financial terms were disclosed.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1122078311?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-09-26 20:10","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1122078311","market":"sg","top_or_hot":-1,"title":"China Medical System Gains NMPA Nod for Uterine Fibroid Drug Trial","media":"SGX Filings","content":"<p>China Medical System Holdings Limited said the National Medical Products Administration approved a clinical trial application for its oral GnRH receptor antagonist CMS-D002 aimed at treating uterine fibroids on Sep, 25 2025, with the formal approval documents received on Sep, 26 2025.</p>\n<p>The trial will evaluate the safety and efficacy of CMS-D002, a small-molecule therapy designed to suppress estrogen and progesterone by competitively blocking GnRH receptors. The candidate had already entered Phase I testing for endometriosis after a prior NMPA clearance on Feb, 06 2024.</p>\n<p>The company stated it is preparing to start the newly approved study and noted that future development of CMS-D002 could include indications such as prostate cancer. No financial terms were disclosed.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>China Medical System Gains NMPA Nod for Uterine Fibroid Drug Trial</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nChina Medical System Gains NMPA Nod for Uterine Fibroid Drug Trial\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1083912268\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/57d1beae95c40ebe9f2698a436562e39);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">SGX Filings </p>\n<p class=\"h-time\">2025-09-26 20:10</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>China Medical System Holdings Limited said the National Medical Products Administration approved a clinical trial application for its oral GnRH receptor antagonist CMS-D002 aimed at treating uterine fibroids on Sep, 25 2025, with the formal approval documents received on Sep, 26 2025.</p>\n<p>The trial will evaluate the safety and efficacy of CMS-D002, a small-molecule therapy designed to suppress estrogen and progesterone by competitively blocking GnRH receptors. The candidate had already entered Phase I testing for endometriosis after a prior NMPA clearance on Feb, 06 2024.</p>\n<p>The company stated it is preparing to start the newly approved study and noted that future development of CMS-D002 could include indications such as prostate cancer. No financial terms were disclosed.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"8A8.SI","symbol_name":"康哲药业控股有限公司","start_time":0,"source_url":"","article_id":"1122078311","we_media_id":"1083912268","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1122078311","pubTimestamp":1758888624,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"SGX Filings","introduction":"Fastest News on SGX Filings ","home_visible":1,"id":"1083912268","head_image":"https://community-static.tradeup.com/news/57d1beae95c40ebe9f2698a436562e39"},"summary":"China Medical System Holdings Limited said the National Medical Products Administration approved a clinical trial application for its oral GnRH receptor antagonist CMS-D002 aimed at treating uterine...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"8A8.SI":"康哲药业控股有限公司"},"translate_title":"康哲药业子宫肌瘤药物试验获NMPA认可","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"8A8.SI":1},"content_text":"China Medical System Holdings Limited said the National Medical Products Administration approved a clinical trial application for its oral GnRH receptor antagonist CMS-D002 aimed at treating uterine fibroids on Sep, 25 2025, with the formal approval documents received on Sep, 26 2025.\nThe trial will evaluate the safety and efficacy of CMS-D002, a small-molecule therapy designed to suppress estrogen and progesterone by competitively blocking GnRH receptors. The candidate had already entered Phase I testing for endometriosis after a prior NMPA clearance on Feb, 06 2024.\nThe company stated it is preparing to start the newly approved study and noted that future development of CMS-D002 could include indications such as prostate cancer. No financial terms were disclosed.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"policyRegulatory,SGX","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.0","shortVersion":"4.36.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1122078311","isCrawlerRequest":true}